Journal
JOURNAL OF THE FORMOSAN MEDICAL ASSOCIATION
Volume 112, Issue 8, Pages 492-496Publisher
ELSEVIER TAIWAN
DOI: 10.1016/j.jfma.2012.09.021
Keywords
carbapenemase; ertapenem-nonsusceptible Enterobacteriaceae; minimal inhibitory concentration; treatment outcomes
Categories
Ask authors/readers for more resources
Among 15 174 non-duplicated Enterobacteriaceae isolates, the prevalence of carbapenem-nonsusceptible Enterobacteriaceae (CNSE) was about 2.5% at a teaching hospital in Taiwan during 2010. Among 117 available isolates of CNSE, 8.6% carried genes encoding carbapenemases. Tigecycline and colistin were the most active agents against carbapenemase-producing and non-producing isolates. Patients infected with CNSE had an all-cause in-hospital mortality of 37.3%, and mortality was similar for infections from carbapenemase producers and non-producers (14-day mortality rates: 22.2% and 21.5%; 30-day mortality rates: 22.2% and 32.3%, respectively). Continuous surveillance of CNSE is recommended in Taiwan. Copyright (C) 2012, Elsevier Taiwan LLC & Formosan Medical Association. All rights reserved.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available